Novo Nordisk has introduced a new pricing strategy for its weight-loss drugs, Ozempic and Wegovy. Starting now, people without insurance can buy the lowest doses for $199 a month for two months. After that, the price jumps to $349. This deal is available through the drugs' websites and select pharmacies. The lower price only applies to the 0. 25 mg and 0. 5 mg doses...
Employers are bracing for a significant hike in health care costs next year, with a median increase of 9 percent expected. This trend is largely driven by the rising use of GLP-1 drugs for obesity and diabetes, as well as the increasing prevalence and cost of cancer treatments. The survey, which included 121 employers covering 11. 6 million people, highlights the gro...
Polycystic ovary syndrome (PCOS) is a common but often misunderstood condition affecting millions of women. It can cause a range of symptoms, from irregular periods and weight gain to infertility and mental health struggles. For years, treatments have been limited, but a new class of drugs originally designed for weight loss and diabetes might offer some relief. Gra...
Semaglutide, the key component in Ozempic and Wegovy, might offer more than just weight loss and diabetes management. Recent research suggests it could also lower dementia risk in type 2 diabetes patients. Scientists from Case Western Reserve University discovered this link, publishing their findings in the Journal of Alzheimer’s Disease. The study analyzed medical ...
Alcohol use disorder remains a major public health challenge in the United States. There are a number of new medications undergoing clinical trials. One promising example is semaglutide, the main ingredient in Ozempic. The drug's success in treating type 2 diabetes has paved the way for its exploration in addiction medicine. The active ingredient, semaglutide, wo...
NYC's health plan for city employees recently scrapped coverage for weight loss drugs called GLP-1s. Almost 400, 000 employees are affected, many of whom find these drugs quite effective. But the city says it'll save money by doing this. Interestingly, other chronic diseases like diabetes usually get full coverage, making this drug treatment something of an outlier. ...
Eli Lilly's recent earnings report wasn't great, with stocks falling after missing growth targets. But don't panic just yet. The dip could be a chance to buy. Think of it like a rollercoaster: there are ups and downs, but the long-term view is what counts. The company had a messy quarter, but it's also investing heavily in the future. They're trying to meet the high ...